Abstract
Respiratory Syncytial Virus (RSV) is a major cause of pneumonia and bronchiolitis in infants and children in Brazil and worldwide, leading to significant hospitalizations during early childhood. Currently, the only preventive measure available through the Unified Health System (SUS) is the monoclonal antibody palivizumab. However, recent advancements in vaccine development have led to pro…